The familiar diuretic spironolactone has taken on new life as a treatment f
or left-sided congestive heart failure. Spironolactone has been shown to de
crease mortality in such patients who are New York Heart Association class
IV. It can be used in addition to agents such as angiotensin-converting enz
yme inhibitors and beta blockers, which also decrease mortality, and diuret
ics and digoxin, which are useful in treating symptoms. Spironolactone is s
afe, easy to use and reasonably priced. More research is necessary to deter
mine the order and combinations of these medications in slowing the progres
sion of this disease.